A clinical study of 77 patients with mucopolysaccharidosis type II
- PMID: 17391446
- DOI: 10.1111/j.1651-2227.2007.00212.x
A clinical study of 77 patients with mucopolysaccharidosis type II
Abstract
Aim: This study aims to assess the clinical features of 77 South American patients (73 Brazilian) with mucopolysaccharidosis type II (MPS II).
Methods: Details of the patients and their disease manifestations were obtained from a review of medical records, interviews with the patients and/or their families, and physical examination of the patients.
Results: Mean birth weight was 3360 g, median age at onset of symptoms was 18 months and median age at diagnosis was 6 years. For the whole sample (median age, 8.2 years; range, 2.8-53.0 years), neurological degeneration, typical pebbly skin lesions, seizures and extensive dermal melanocytosis were found in 23.3, 13.0, 13.0 and 1.3% of the cases, respectively. The most frequently reported echocardiogram abnormality was mitral valve regurgitation. Refraction errors were the most common ophthalmological manifestation. The following characteristics were found to be associated with the severe form of MPS II: earlier age at biochemical diagnosis, higher levels of urinary glycosaminoglycans, language development delay, behavioural disturbances, poor school performance and mental retardation.
Conclusion: Our results suggest that there is a considerable delay between the onset of signs and symptoms and the diagnosis of MPS II in Brazil (and probably in South America as well), and that many complications of this disease are underdiagnosed and undertreated. Therefore, the implementation of programmes aiming to increase the awareness of the disease, the availability of biochemical diagnostic tests and the provision of better support to affected patients is urgently needed.
Comment in
-
Update on mucopolysaccharidosis type II.Acta Paediatr. 2007 Apr;96(455):55. doi: 10.1111/j.1651-2227.2007.00210.x. Acta Paediatr. 2007. PMID: 17391444 No abstract available.
Similar articles
-
Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan.Mol Genet Metab. 2012 Nov;107(3):513-20. doi: 10.1016/j.ymgme.2012.09.004. Epub 2012 Sep 7. Mol Genet Metab. 2012. PMID: 23022072
-
Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.Pediatr Pulmonol. 2014 Mar;49(3):277-84. doi: 10.1002/ppul.22774. Epub 2013 Feb 8. Pediatr Pulmonol. 2014. PMID: 23401495
-
Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI.Clin Genet. 2004 Sep;66(3):208-13. doi: 10.1111/j.1399-0004.2004.00277.x. Clin Genet. 2004. PMID: 15324318
-
Management of the behavioural manifestations of Hunter syndrome.Br J Nurs. 2016 Jan 14-27;25(1):22, 24, 26-30. doi: 10.12968/bjon.2016.25.1.22. Br J Nurs. 2016. PMID: 26768041 Review.
-
Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two-year follow-up of the first Italian patient and review of the literature.Pediatr Med Chir. 1995 May-Jun;17(3):227-35. Pediatr Med Chir. 1995. PMID: 7567644 Review.
Cited by
-
Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey.Mol Genet Metab Rep. 2023 Sep 8;37:101005. doi: 10.1016/j.ymgmr.2023.101005. eCollection 2023 Dec. Mol Genet Metab Rep. 2023. PMID: 38053935 Free PMC article.
-
Enhanced osteoblastic differentiation of parietal bone in a novel murine model of mucopolysaccharidosis type II.Mol Genet Metab Rep. 2023 Nov 11;37:101021. doi: 10.1016/j.ymgmr.2023.101021. eCollection 2023 Dec. Mol Genet Metab Rep. 2023. PMID: 38053930 Free PMC article.
-
Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome.Mol Genet Metab Rep. 2023 Jan 20;34:100956. doi: 10.1016/j.ymgmr.2023.100956. eCollection 2023 Mar. Mol Genet Metab Rep. 2023. PMID: 36704405 Free PMC article.
-
Impact of the Timing of Enzyme Replacement Therapy Initiation and Cognitive Impairment Status on Outcomes for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review.J Health Econ Outcomes Res. 2022 Aug 29;9(2):67-76. doi: 10.36469/001c.36540. eCollection 2022. J Health Econ Outcomes Res. 2022. PMID: 36168594 Free PMC article.
-
Comparison of growth dynamics in different types of MPS: an attempt to explain the causes.Orphanet J Rare Dis. 2022 Sep 5;17(1):339. doi: 10.1186/s13023-022-02486-4. Orphanet J Rare Dis. 2022. PMID: 36064607 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
